NCT03875495View on ClinicalTrials.gov

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

April 2, 2021

Study Completion Date

April 2, 2021

Conditions

Multiple Myeloma

Interventions

DRUG

Temferon

Genetically modified autologous HSPCs

Trial Locations (1)

20132

Ospedale San Raffaele, Milan

Sponsors

Lead Sponsor

Genenta Science

All Listed Sponsors

collaborator

IRCCS San Raffaele

OTHER

lead

Genenta Science

INDUSTRY

NCT03875495 - A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | Biotech Hunter | Biotech Hunter